Elcatonin
Appearance
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ECHA InfoCard | 100.056.703 |
Chemical and physical data | |
Formula | C148H244N42O47 |
Molar mass | 3363.827 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Elcatonin is a calcitonin derivative used as an anti-parathyroid agent.
It is transformed from eel's calcitonin by changing the S-S bond into a stable C-N bond. It inhibits the absorption and autolysis of bones and thus leads to lowering of blood calcium. It inhibits bone salts from dissolving and transferring and promotes the excretion of calcium and phosphorus in the urine. It inhibits renal tubules from reabsorbing calcium, phosphorus and sodium and keeps blood calcium at a normal level.[citation needed] It is mainly used for remitting or eliminating pain caused by osteoporosis.[1][2]
References
[edit]- ^ Yoh K, Uzawa T, Orito T, Tanaka K (2012). "Improvement of Quality of Life (QOL) in Osteoporotic Patients by Elcatonin Treatment: A Trial Taking the Participants' Preference into Account". Japanese Clinical Medicine. 3: 9–14. doi:10.4137/JCM.S8291. PMC 3738553. PMID 23946680.
- ^ Tanaka S, Yoshida A, Kono S, Oguma T, Hasegawa K, Ito M (September 2017). "Effectiveness of elcatonin for alleviating pain and inhibiting bone resorption in patients with osteoporotic vertebral fractures". Journal of Bone and Mineral Metabolism. 35 (5): 544–553. doi:10.1007/s00774-016-0791-6. PMID 27830386. S2CID 21904979.